Is Boai NKY Medical Holdings Ltd.'s (SZSE:300109) Recent Stock Performance Tethered To Its Strong Fundamentals?
Is Boai NKY Medical Holdings Ltd.'s (SZSE:300109) Recent Stock Performance Tethered To Its Strong Fundamentals?
Most readers would already be aware that Boai NKY Medical Holdings' (SZSE:300109) stock increased significantly by 22% over the past three months. Given the company's impressive performance, we decided to study its financial indicators more closely as a company's financial health over the long-term usually dictates market outcomes. Particularly, we will be paying attention to Boai NKY Medical Holdings' ROE today.
大多数读者应该已经知道,新开源医疗控股(SZSE:300109)的股票在过去三个月中显著上涨了22%。 鉴于公司的出色表现,我们决定更加密切地研究其财务指标,因为公司的长期财务状况通常决定市场结果。 特别地,我们今天将关注新开源医疗控股的roe。
ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. Put another way, it reveals the company's success at turning shareholder investments into profits.
ROE或股东权益报酬率是一种有用的工具,用于评估一家公司能否有效地利用来自股东的投资产生回报。换句话说,它揭示了公司将股东的投资变成利润的成功程度。
How Is ROE Calculated?
净资产收益率怎么计算?
The formula for return on equity is:
权益回报率的计算公式是:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
净资产收益率 = 净利润(从持续经营中获得)÷ 股东权益
So, based on the above formula, the ROE for Boai NKY Medical Holdings is:
因此,根据上述公式,新开源医疗控股的roe为:
13% = CN¥487m ÷ CN¥3.6b (Based on the trailing twelve months to March 2024).
13%= CN¥48700万 ÷ CN¥36亿(基于截至2024年3月的过去十二个月)。
The 'return' is the profit over the last twelve months. That means that for every CN¥1 worth of shareholders' equity, the company generated CN¥0.13 in profit.
“回报”是过去12个月的利润。这意味着对于每一元股东权益价值,该公司产生了0.13元利润。
What Is The Relationship Between ROE And Earnings Growth?
ROE与盈利增长之间的关系是什么?
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.
我们已经确定ROE作为一个高效的盈利规模可以评估公司未来的收益。根据公司选择再投资或保留多少利润,我们可以评估公司未来盈利的能力。假设其他所有条件均保持不变,ROE和利润留存率越高,相对于没有这些特点的公司,公司的增长率就越高。
Boai NKY Medical Holdings' Earnings Growth And 13% ROE
新开源医疗控股净利润增长和13% roe
At first glance, Boai NKY Medical Holdings seems to have a decent ROE. On comparing with the average industry ROE of 6.3% the company's ROE looks pretty remarkable. This probably laid the ground for Boai NKY Medical Holdings' significant 40% net income growth seen over the past five years. However, there could also be other causes behind this growth. For example, it is possible that the company's management has made some good strategic decisions, or that the company has a low payout ratio.
乍一看,新开源医疗控股的roe看起来还不错。与行业平均roe水平6.3%相比,该公司的roe看起来非常显著。这可能是新开源医疗控股在过去五年中净利润增长40%的主要原因。但是,这种增长背后还可能有其他原因。例如,公司管理层可能做出了一些好的战略决策,或者公司的分红比率很低。
We then compared Boai NKY Medical Holdings' net income growth with the industry and we're pleased to see that the company's growth figure is higher when compared with the industry which has a growth rate of 8.0% in the same 5-year period.
然后,我们将新开源医疗控股的净利润增长与行业进行了比较,我们很高兴地看到,在同一5年期内,该公司的增长率比8.0%的行业增长率要高。
Earnings growth is an important metric to consider when valuing a stock. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. Doing so will help them establish if the stock's future looks promising or ominous. If you're wondering about Boai NKY Medical Holdings''s valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.
净利润增长是在估值股票时要考虑的重要指标。投资者需要判断的是,预期的盈利增长或缺乏盈利增长是否已经融入股票价格中。这样做将帮助他们确定该股票的未来前景是光明还是黑暗。如果您想了解新开源医疗控股的估值,请查看其市盈率相对于同行业的比较。
Is Boai NKY Medical Holdings Making Efficient Use Of Its Profits?
新开源医疗控股是否有效利用其利润?
Boai NKY Medical Holdings' three-year median payout ratio is a pretty moderate 43%, meaning the company retains 57% of its income. By the looks of it, the dividend is well covered and Boai NKY Medical Holdings is reinvesting its profits efficiently as evidenced by its exceptional growth which we discussed above.
新开源医疗控股的三年中位数分红比率相当适度,为43%,意味着公司保留了其收入的57%。从外观上看,股息得到了很好的覆盖,新开源医疗控股正在有效地 reinvesting其利润,正如我们上面讨论过的那样,这表现出其非凡的增长。
Moreover, Boai NKY Medical Holdings is determined to keep sharing its profits with shareholders which we infer from its long history of paying a dividend for at least ten years.
此外,新开源医疗控股决心继续与股东分享其利润,我们推断这是根据其至少支付股息十年的长期历史记录而推出的。
Conclusion
结论
Overall, we are quite pleased with Boai NKY Medical Holdings' performance. In particular, it's great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a sizeable growth in its earnings. If the company continues to grow its earnings the way it has, that could have a positive impact on its share price given how earnings per share influence long-term share prices. Remember, the price of a stock is also dependent on the perceived risk. Therefore investors must keep themselves informed about the risks involved before investing in any company. Our risks dashboard will have the 1 risk we have identified for Boai NKY Medical Holdings.
总体而言,我们对新开源医疗控股的表现非常满意。特别是看到公司正在大力投资其业务,并且以高回报率,导致其收益大幅增长。如果公司继续像过去那样增长其收益,将对其股票价格产生积极影响,因为每股收益对长期股价产生影响。请记住,股票价格也取决于 perceived risk。因此,投资者必须在投资任何公司之前,了解其风险。我们的风险仪表板将显示我们为新开源医疗控股确定的1个风险。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或电邮 editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。